iBio

iBio P/B

The P/B (Price-to-Book Ratio) of iBio (IBIO) as of Nov 10, 2026 is 0.85. In the previous year, P/B (Price-to-Book Ratio) was 4.88 — a change of -82.64% (lower).

P/B

0.85

YoY

-82.64%

Last updated:

P/B (Price-to-Book Ratio) of iBio is 2026 0.85 . P/B (Price-to-Book Ratio) of iBio was 2025 4.88 . It decreases by -82.64% lower compared to the previous year.

The iBio P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2019
29.45 USD
Jan 1, 2020
1.28 USD
Jan 1, 2021
0.67 USD
Jan 1, 2022
1.14 USD
Jan 1, 2023
4.72 USD
Jan 1, 2024
3.40 USD
Jan 1, 2025
4.88 USD
Jan 1, 2026
0.85 USD
The iBio P/B history
YEARP/BYoY
0.85-82.64%
4.88+43.31%
3.40-27.87%
4.72+312.75%
1.14+71.04%
0.67-47.86%
1.28-95.65%
29.45+556.35%
4.49-44.86%
8.14+11.48%
7.30+13.02%
6.46-45.69%
11.89—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

iBio Stock analysis

What does iBio do? iBio, Inc. generates revenue through the commercialization of its plant-based protein expression technologies, which are used for developing vaccines and therapeutic proteins. The company's iBioLaunch technology and iBioModulator platform enable the production of biologics in hydroponically grown green plants, targeting fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of plasma-derived products. Clients and collaborators purchase product development and manufacturing services, leveraging iBio's transformative platform for biologics production. The firm focuses on both its own product candidates and providing services to external partners in the biopharmaceutical sector. iBio's business model centers on offering its proprietary technologies as a service to clients, with a focus on developing and manufacturing biologics through plant-based systems. The company's technologies are applicable across multiple therapeutic areas, including fibrotic disease treatments, vaccine development, and enzyme replacement therapies. By providing these services, iBio supports clients in creating advanced biopharmaceutical products without the need for traditional manufacturing infrastructure. The company's revenue streams include the sale of its iBioLaunch and iBioModulator platforms, as well as product development and manufacturing services for biopharmaceutical clients. These services are tailored to meet the needs of partners seeking efficient, scalable production methods for biologics. iBio's focus on plant-based production differentiates it in the market, appealing to clients looking for innovative approaches to biologic manufacturing. iBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about iBio stock

P/B (Price-to-Book Ratio) of iBio is 0.85 in 2026.

P/B (Price-to-Book Ratio) of iBio changed from 4.88 to 0.85, representing a -82.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) iBio since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s iBio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — iBio

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — iBio